Elanco Animal Health (NYSE:ELAN) Price Target Raised to $24.00 at Morgan Stanley

Elanco Animal Health (NYSE:ELAN) had its target price hoisted by research analysts at Morgan Stanley from $22.00 to $24.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Morgan Stanley’s target price would indicate a potential downside of 11.58% from the stock’s previous close.

ELAN has been the subject of a number of other research reports. KeyCorp upped their price target on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday. Weiss Ratings restated a “sell (d+)” rating on shares of Elanco Animal Health in a research note on Monday, December 29th. Barclays began coverage on shares of Elanco Animal Health in a research note on Tuesday, December 9th. They set an “overweight” rating and a $30.00 price target on the stock. Zacks Research lowered shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. Finally, Piper Sandler upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their target price for the company from $24.00 to $30.00 in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $27.67.

Elanco Animal Health Stock Up 2.9%

NYSE ELAN traded up $0.76 during trading hours on Wednesday, hitting $27.14. The company had a trading volume of 1,053,709 shares, compared to its average volume of 4,593,686. The firm’s 50 day moving average is $23.97 and its 200 day moving average is $21.62. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. Elanco Animal Health has a fifty-two week low of $8.02 and a fifty-two week high of $27.69. The company has a market capitalization of $13.49 billion, a price-to-earnings ratio of 450.93, a P/E/G ratio of 3.69 and a beta of 1.87.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the prior year, the business earned $0.14 earnings per share. The company’s revenue was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Sell-side analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 22,000 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were bought at an average cost of $21.75 per share, with a total value of $478,500.00. Following the completion of the acquisition, the chief executive officer owned 167,000 shares of the company’s stock, valued at approximately $3,632,250. This trade represents a 15.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lawrence Erik Kurzius purchased 10,000 shares of Elanco Animal Health stock in a transaction dated Friday, December 12th. The stock was acquired at an average price of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the transaction, the director owned 131,773 shares in the company, valued at approximately $2,806,764.90. The trade was a 8.21% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 43,450 shares of company stock worth $937,883 in the last ninety days. 0.89% of the stock is currently owned by company insiders.

Institutional Trading of Elanco Animal Health

Institutional investors and hedge funds have recently made changes to their positions in the stock. NewEdge Advisors LLC boosted its position in Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after purchasing an additional 627 shares during the period. SJS Investment Consulting Inc. boosted its holdings in shares of Elanco Animal Health by 2,563.5% during the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after acquiring an additional 1,333 shares during the period. Huntington National Bank grew its position in shares of Elanco Animal Health by 136.7% during the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after acquiring an additional 1,087 shares during the last quarter. Root Financial Partners LLC grew its position in shares of Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after acquiring an additional 592 shares during the last quarter. Finally, Uniplan Investment Counsel Inc. acquired a new stake in shares of Elanco Animal Health in the 4th quarter worth about $41,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health News Roundup

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q4 beat and stronger 2026 targets — Elanco reported Q4 revenue of $1.144B (+12% yr/yr) and adjusted EPS of $0.13, beating estimates; it set FY2026 revenue guidance of $4.95–5.02B, raised its 2026 innovation revenue target to $1.15B, and guided adjusted EPS $1.00–1.06 while targeting lower net leverage. Elanco Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Analyst upgrade — Leerink Partners raised its price target on ELAN to $30 and kept an outperform rating, signaling institutional confidence in the outlook and providing upside to the share valuation. Leerink raises price target to $30 (Benzinga)
• Positive Sentiment: Shares hit recent highs — Coverage noted ELAN reached a 52‑week high after the Q4 print and 2026 outlook, reflecting positive market reaction to growth/guidance beats. Elanco hits 52-week high after Q4 results (Seeking Alpha)
• Neutral Sentiment: CEO media appearance — CEO Jeff Simmons spoke one‑on‑one with Jim Cramer (visibility event) to discuss the quarter, strategy and the “Big 6” product rollouts — useful for investor messaging but not a direct financial driver. Elanco CEO Jeff Simmons on Jim Cramer (CNBC)
• Neutral Sentiment: Earnings materials available — The earnings slide deck and call transcript provide granular metrics (adjusted EBITDA margin, innovation revenue breakdown, product momentum) for investors doing deeper fundamental work. Q4 2025 earnings call transcript (Seeking Alpha)
• Negative Sentiment: Margin pressure flagged — Several outlets highlighted concerns around margins and short‑term profitability (and some noted the stock initially slipped on those worries), pointing to investor focus on whether margin recovery will match top‑line gains. Elanco beats estimates but shares edge down on margin concerns (Investing.com)

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.